Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04902833 · ClinicalTrials.gov registry record
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
A clinical trial of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT04902833 is a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04902833, a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04902833
The ClinicalTrials.gov registry entry for NCT04902833 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (14% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT04902833 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04902833 about?
NCT04902833 is a clinical study titled "Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms". This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
What is the current status of trial NCT04902833?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2022-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04902833 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT04902833?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT04902833?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04902833 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
RECRUITING
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.